Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Gene Modification and Three-Dimensional Scaffolds as Novel Tools to Allow the Use of Postnatal Thymic Epithelial Cells for Thymus Regeneration Approaches.

Bortolomai I, Sandri M, Draghici E, Fontana E, Campodoni E, Marcovecchio GE, Ferrua F, Perani L, Spinelli A, Canu T, Catucci M, Di Tomaso T, Sergi Sergi L, Esposito A, Lombardo A, Naldini L, Tampieri A, Hollander GA, Villa A, Bosticardo M.

Stem Cells Transl Med. 2019 May 29. doi: 10.1002/sctm.18-0218. [Epub ahead of print]

2.

Autonomous role of Wiskott-Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation.

Sereni L, Castiello MC, Marangoni F, Anselmo A, di Silvestre D, Motta S, Draghici E, Mantero S, Thrasher AJ, Giliani S, Aiuti A, Mauri P, Notarangelo LD, Bosticardo M, Villa A.

J Allergy Clin Immunol. 2018 Oct;142(4):1272-1284. doi: 10.1016/j.jaci.2017.12.1000. Epub 2018 Feb 6.

3.

Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation.

Capo V, Castiello MC, Fontana E, Penna S, Bosticardo M, Draghici E, Poliani LP, Sergi Sergi L, Rigoni R, Cassani B, Zanussi M, Carrera P, Uva P, Dobbs K, Sacchetti N, Notarangelo LD, van Til NP, Wagemaker G, Villa A.

J Allergy Clin Immunol. 2018 Sep;142(3):928-941.e8. doi: 10.1016/j.jaci.2017.11.015. Epub 2017 Dec 11.

4.

In Vivo Chronic Stimulation Unveils Autoreactive Potential of Wiskott-Aldrich Syndrome Protein-Deficient B Cells.

Castiello MC, Pala F, Sereni L, Draghici E, Inverso D, Sauer AV, Schena F, Fontana E, Radaelli E, Uva P, Cervantes-Luevano KE, Benvenuti F, Poliani PL, Iannacone M, Traggiai E, Villa A, Bosticardo M.

Front Immunol. 2017 May 2;8:490. doi: 10.3389/fimmu.2017.00490. eCollection 2017.

5.

Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.

Carriglio N, Klapwijk J, Hernandez RJ, Vezzoli M, Chanut F, Lowe R, Draghici E, Nord M, Albertini P, Cristofori P, Richards J, Staton H, Appleby J, Aiuti A, Sauer AV.

Hum Gene Ther Clin Dev. 2017 Mar;28(1):17-27. doi: 10.1089/humc.2016.191. Erratum in: Hum Gene Ther Clin Dev. 2017 Jun;28(2):116.

PMID:
28319446
6.

Development of central nervous system autoimmunity is impaired in the absence of Wiskott-Aldrich syndrome protein.

Bosticardo M, Musio S, Fontana E, Angiari S, Draghici E, Constantin G, Poliani PL, Pedotti R, Villa A.

PLoS One. 2014 Jan 23;9(1):e86942. doi: 10.1371/journal.pone.0086942. eCollection 2014.

7.

Wiskott-Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity.

Catucci M, Zanoni I, Draghici E, Bosticardo M, Castiello MC, Venturini M, Cesana D, Montini E, Ponzoni M, Granucci F, Villa A.

Eur J Immunol. 2014 Apr;44(4):1039-45. doi: 10.1002/eji.201343935. Epub 2014 Jan 13.

8.

The involvement of TGF-β1 and CTGF in regional gingival overgrowth.

Niţulescu EA, Crăiţoiu MM, Baniţă MI, Drăghici E, Crăiţoiu Ş.

Rom J Morphol Embryol. 2012;53(1):143-50.

9.

Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome.

Scaramuzza S, Biasco L, Ripamonti A, Castiello MC, Loperfido M, Draghici E, Hernandez RJ, Benedicenti F, Radrizzani M, Salomoni M, Ranzani M, Bartholomae CC, Vicenzi E, Finocchi A, Bredius R, Bosticardo M, Schmidt M, von Kalle C, Montini E, Biffi A, Roncarolo MG, Naldini L, Villa A, Aiuti A.

Mol Ther. 2013 Jan;21(1):175-84. doi: 10.1038/mt.2012.23. Epub 2012 Feb 28. Erratum in: Mol Ther. 2016 Jun;24(6):1159.

10.

Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.

Catucci M, Prete F, Bosticardo M, Castiello MC, Draghici E, Locci M, Roncarolo MG, Aiuti A, Benvenuti F, Villa A.

Gene Ther. 2012 Dec;19(12):1150-8. doi: 10.1038/gt.2011.202. Epub 2011 Dec 22.

11.

Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome.

Bosticardo M, Draghici E, Schena F, Sauer AV, Fontana E, Castiello MC, Catucci M, Locci M, Naldini L, Aiuti A, Roncarolo MG, Poliani PL, Traggiai E, Villa A.

J Allergy Clin Immunol. 2011 Jun;127(6):1376-84.e5. doi: 10.1016/j.jaci.2011.03.030. Epub 2011 Apr 29.

PMID:
21531013
12.

Corrigendum to "Evidence for Long-term Efficacy and Safety of Gene Therapy for Wiskott-Aldrich Syndrome in Preclinical Models".

Marangoni F, Bosticardo M, Charrier S, Draghici E, Locci M, Scaramuzza S, Panaroni C, Ponzoni M, Sanvito F, Doglioni C, Liabeuf M, Gjata B, Montus M, Siminovitch K, Aiuti A, Naldini L, Dupré L, Roncarolo MG, Galy A, Villa A.

Mol Ther. 2009 Jul;17(7):1300. doi: 10.1038/mt.2009.61. Epub 2016 Dec 6. No abstract available.

13.

The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function.

Locci M, Draghici E, Marangoni F, Bosticardo M, Catucci M, Aiuti A, Cancrini C, Marodi L, Espanol T, Bredius RG, Thrasher AJ, Schulz A, Litzman J, Roncarolo MG, Casorati G, Dellabona P, Villa A.

J Exp Med. 2009 Apr 13;206(4):735-42. doi: 10.1084/jem.20081773. Epub 2009 Mar 23.

14.

Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.

Marangoni F, Bosticardo M, Charrier S, Draghici E, Locci M, Scaramuzza S, Panaroni C, Ponzoni M, Sanvito F, Doglioni C, Liabeuf M, Gjata B, Montus M, Siminovitch K, Aiuti A, Naldini L, Dupré L, Roncarolo MG, Galy A, Villa A.

Mol Ther. 2009 Jun;17(6):1073-82. doi: 10.1038/mt.2009.31. Epub 2009 Mar 3. Erratum in: Mol Ther. 2009 Jul;17(7):1300.

15.

Contributions on the study of the compressive strength of the light-cured composite resins.

Manolea H, Degeratu S, Deva V, Coles E, Draghici E.

Curr Health Sci J. 2009 Jan;35(1):60-3. Epub 2009 Mar 21.

16.

Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells.

Hauben E, Gregori S, Draghici E, Migliavacca B, Olivieri S, Woisetschläger M, Roncarolo MG.

Blood. 2008 Aug 15;112(4):1214-22. doi: 10.1182/blood-2007-08-109843. Epub 2008 Jun 11.

17.

The role of tissue adaptation and graft size in immune tolerance.

Hauben E, Roncarolo MG, Draghici E, Nevo U.

Transpl Immunol. 2007 Nov;18(2):122-5. Epub 2007 Jun 15.

PMID:
18005855
18.

Relevance of hyperglycemia on the timing of functional loss of allogeneic islet transplants: implication for mouse model.

Melzi R, Battaglia M, Draghici E, Bonifacio E, Piemonti L.

Transplantation. 2007 Jan 27;83(2):167-73.

PMID:
17264813
19.

Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells.

Battaglia M, Stabilini A, Draghici E, Migliavacca B, Gregori S, Bonifacio E, Roncarolo MG.

Diabetes. 2006 Jun;55(6):1571-80.

20.

Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance.

Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, Bonifacio E, Roncarolo MG.

Diabetes. 2006 Jan;55(1):40-9.

Supplemental Content

Loading ...
Support Center